Pipeline

Product Candidate
Indication
Combination
Preclinical
Phase I
Phase II
Centers and Partners
SurVaxM
Glioblastoma (GBM)
Standard of Care
Potential for Orphan / Breakthrough Therapy Designation
Roswell Park Cancer Institute
Dana Farber Cancer Institute
Cleveland Clinic
SurVaxM
Glioblastoma
anti-PD1
Roswell Park
Cleveland Clinic
SurVaxM
Multiple Myeloma
REVLIMID®
Roswell Park Cancer Institute
Celgene
SurVaxM
Auto-immune Diseases
TBD
mAb (MV2C2)
Cancers / Auto-immune Diseases
TBD
CAR-T (MV97183) Solid Tumors
Solid Tumors
TBD
Sur-Dx
Cancer
TBD
Product Candidate
SurVaxM
SurVaxM
Indication
Glioblastoma (GBM)
Glioblastoma
Combination
Potential for Orphan /
anti-PD1
Preclinical
Phase I
Potential for Orphan / Breakthrough Therapy Designation
Phase II
Centers and Partners
Roswell Park Cancer Institute Dana Farber Cancer Institute Cleveland Clinic
Roswell Park Cleveland Clinic
Product Candidate
SurVaxM
SurVaxM
Indication
Multiple Myeloma
Auto-immune Diseases
Combination
REVLIMID®
TBD
Preclinical
Phase I
Phase II
Centers and Partners
Roswell Park Cancer Institute Celgene
Product Candidate
mAb (MV2C2)
CAR-T (MV97183) Solid Tumors
Indication
Cancers / Auto-immune Diseases
Solid Tumors
Combination
TBD
TBD
Preclinical
Sur-Dx
Phase I
Cancer
Phase II
TBD
Centers and Partners